Novosteo

About:

Novosteo, test the efficacy of a new drug to help reduce complications from a broken bone due to a fall.

Top Investors: National Institutes of Health, Purdue Research Foundation, BioCrossroads, Elevate Ventures, Kairos Ventures

Description:

Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created a proprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.

Total Funding Amount:

$7.95M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Indiana, Pennsylvania, United States

Founded Date:

2017-01-01

Founders:

Philip Low, Stewart Low

Number of Employees:

1-10

Last Funding Date:

2021-01-13

IPO Status:

Private

Industries: